Arrhythmia

iRhythm Technologies to Report Third Quarter 2021 Financial Results on November 4, 2021

Thursday, October 21, 2021 - 9:05pm

SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the third quarter 2021 after the close of trading on Thursday, November 4, 2021.

Key Points: 
  • SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the third quarter 2021 after the close of trading on Thursday, November 4, 2021.
  • The companys management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m.
  • iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed.
  • The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

inHEART appoints industry veteran Todor Jeliaskov as new CEO to drive commercial growth

Thursday, October 21, 2021 - 1:43pm

PESSAC, France, Oct. 21, 2021 /PRNewswire/ -- inHEART , the leader in image guidance for treatment of cardiac arrhythmias, has appointed Todor Jeliaskov as CEO.

Key Points: 
  • PESSAC, France, Oct. 21, 2021 /PRNewswire/ -- inHEART , the leader in image guidance for treatment of cardiac arrhythmias, has appointed Todor Jeliaskov as CEO.
  • Todor Jeliaskov will work closely with co-founder and former CEO Jean-Marc Peyrat, who transitions to the role of CTO at inHEART.
  • "I am thrilled to welcome Todor as our new CEO," said Jean-Marc Peyrat, co-founder of inHEART.
  • Before inHEART, Todor Jeliaskov was CEO of NuVera Medical, acquired by Biosense Webster (Johnson & Johnson) in November 2020.

Remote Monitoring Devices More Common; Misconceptions May Impact Usage

Monday, October 18, 2021 - 2:35pm

(1) The COVID-19 pandemic accelerated the use of remote monitoring and diagnostic devices, especially among cardiology practices.

Key Points: 
  • (1) The COVID-19 pandemic accelerated the use of remote monitoring and diagnostic devices, especially among cardiology practices.
  • Remote patient monitoring and diagnostic devices are used for intermittent or continuous monitoring of patients with heart problems.
  • Only remote monitoring and diagnostic devices , such as InfoBionic's platform, generate automated reports that can be accessed anytime, 24/7 through a secure HIPAA-compliant portal.
  • "The Technology, Devices, and Benefits of Remote Patient Monitoring in the Healthcare Industry."

Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx(TM), into Brazil, Mexico, and Canada

Monday, October 18, 2021 - 12:27pm

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease

Key Points: 
  • Cardiol has now received requisite government approvals from health regulators in Brazil, Mexico, and Canada to initiate several additional hospital centers in these countries.
  • Clinical site activation is underway in Brazil and Mexico and the first hospital centers are initiating patient enrollment.
  • The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is being investigated in a Phase II/III outcomes study (the LANCER trial).
  • These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information.

First Patients Treated in Southern Europe with Stereotaxis Genesis Robotic Technology

Monday, October 18, 2021 - 12:00pm

Electrophysiologists at Princess Grace Hospital have been among the pioneers of robotic cardiac ablation in Europe, becoming early adopters of Stereotaxis technology in 2006.

Key Points: 
  • Electrophysiologists at Princess Grace Hospital have been among the pioneers of robotic cardiac ablation in Europe, becoming early adopters of Stereotaxis technology in 2006.
  • Since then, more than 1,000 patients in Monaco have benefited from the precision and safety of Robotic Magnetic Navigation.
  • Dr. Gabriel Latcu, head of electrophysiology and deputy head of cardiology services at Princess Grace Hospital, has successfully treated the first patients with the new Genesis Robot, the first procedures performed with the technology in Southern Europe.
  • Robotic Magnetic Navigation has been a central technology in enabling us to successfully treat and research complex arrhythmias, says Dr. Latcu.

OneProjects Announces $17 Million in New Financing to Advance Development of 4D Cardiac Imaging Technology

Thursday, October 14, 2021 - 12:30pm

OneProjects, developer of four-dimensional (4D) cardiac imaging technology, today announced a total of $17 million in new financing for the company, including an $8 million Series A2 financing and two grants worth $9 million.

Key Points: 
  • OneProjects, developer of four-dimensional (4D) cardiac imaging technology, today announced a total of $17 million in new financing for the company, including an $8 million Series A2 financing and two grants worth $9 million.
  • The grants were awarded by the Irish governments Disruptive Technologies Innovation Fund ($6 million) and the EIC Accelerator ($3 million).
  • The company will use the new funds to complete product development, conduct clinical trials, gain FDA clearance and prepare for U.S. commercialization of the first product developed from its proprietary 4D cardiac imaging platform, VERAFEYE.
  • This technology is designed to improve the treatment of atrial fibrillation and other cardiac arrhythmias, and can also be applied to benefit structural heart procedures.

iRhythm® Technologies Announces Changes to Its Board of Directors

Tuesday, October 12, 2021 - 9:05pm

On behalf of the entire iRhythm team, I am pleased to welcome Karen to our Board of Directors, said Quentin Blackford, iRhythm President and CEO.

Key Points: 
  • On behalf of the entire iRhythm team, I am pleased to welcome Karen to our Board of Directors, said Quentin Blackford, iRhythm President and CEO.
  • Karen is a renowned HR leader in the healthcare and insurance industries and brings a wealth of experience and unique perspectives to iRhythm.
  • I am honored to join the iRhythm Board, commented Ms. Ling on her appointment.
  • On Mr. Scotts departure from the Board, Abhi Talwalkar, Chairman of the iRhythm Board, commented, We would like to thank Ray for his service over the past eight years.

BioSig’s PURE EP System to be Featured in a Live Patient Case During Annual International Symposium on Ventricular Arrhythmias

Tuesday, October 12, 2021 - 2:15pm

VT 2021 has been developed to meet the educational needs of electrophysiologists, cardiologists, and other physicians and associated professionals interested in the pathophysiology and management of ventricular arrhythmias.

Key Points: 
  • VT 2021 has been developed to meet the educational needs of electrophysiologists, cardiologists, and other physicians and associated professionals interested in the pathophysiology and management of ventricular arrhythmias.
  • Treatments for ventricular arrhythmias have historically been complex due to the very challenging nature of these conditions.
  • To date, over 70 physicians have completed over 1500 patient cases with the PURE EP System across thirteen clinical sites.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

AliveCor Launches AliveCor Labs

Tuesday, October 12, 2021 - 2:00pm

MOUNTAIN VIEW, Calif., Oct. 12, 2021 /PRNewswire/ -- AliveCor , a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology,todayannounced the launch of AliveCor Labs, further establishing the company's footprint in enterprise class clinical workflows.

Key Points: 
  • MOUNTAIN VIEW, Calif., Oct. 12, 2021 /PRNewswire/ -- AliveCor , a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology,todayannounced the launch of AliveCor Labs, further establishing the company's footprint in enterprise class clinical workflows.
  • Starting today, AliveCor Labs offers a full suite of cardiac monitoring services featuring AliveCor's KardiaMobile 6L, the most clinically-validated six-lead personal electrocardiogram device in the world.
  • "AliveCor Labs offers providers a reimbursed means of monitoring cardiac events with the most well-known personal ECG in the world," said Priya Abani, CEO, AliveCor.
  • AliveCor Labs is the trademark under which AliveCor Inc. provides services from CardioLabs.

International Journal of Cardiology Publishes Data Demonstrating Superior Outcomes of Stereotaxis Robotic Cardiac Ablation in Pediatric Patients

Tuesday, October 12, 2021 - 12:00pm

The 223-patient study, conducted at Erasmus Medical Center in Rotterdam, the Netherlands, compared Robotic Magnetic Navigation (RMN) guided cardiac ablation to manual radiofrequency (RF) ablation and manual cryoablation.

Key Points: 
  • The 223-patient study, conducted at Erasmus Medical Center in Rotterdam, the Netherlands, compared Robotic Magnetic Navigation (RMN) guided cardiac ablation to manual radiofrequency (RF) ablation and manual cryoablation.
  • We are excited to share data from this large long-term comparative study, said Dr. Anne-Marie Noten, author of the publication.
  • It builds upon the significant body of evidence supporting the clinical value of robotics for arrhythmia patients, particularly the most vulnerable patients with complex disease.
  • Although cardiac ablation is a common treatment for AV(N)RT, there is risk of procedural complications, and the impact of procedural radiation on pediatric patients is a concern.